Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: USPTO Page 26 to be considered

First, my apologies to the board. I've gotten carried away yet again and am putting on the breaks. I haven't even read all the posts since yesterday, and possible responses may remain unread until after this post. I admit that it seems my head is spinning with subtle excitement, and it appears the only way I can stop the spinning is to firmly implant it somewhere.....another job well done! LOL

I had emmersed myself in silly detail over specific words.

To finalize that, Bill's post provides a path.... I see the settlement as a piece of paper submitted to the court saying "we've settled", and virtually nothing more. The issue with the court is that the matter is resolved - regardless of the terms. The litigant's agreed terms for the settlement will reside in licensing agreements, which may include anything - but at minimum will include the '148 and '336. That's it....

Now I'm going to just try and STFU until we get a PR or PACER.

I do still wonder whether we'll see individual Js drop out (settle/license) one by one or all at once.

That's one question that remains, along with the when, how much, what's included, and how soon other infringers on notice will cave.

All questions none of us KNOW the answers to, and will hopefully be revealed this week and the ones that follow (re: new licensees).

I suppose there is one big wild card still out, and that would be no settlement. This has been addressed and seems highly unlikely. And if it did happen, I strongly suspect that our team would just pull the trigger and file a MSJ - thereby further forcing the issue.

Now, until we get some news, I intend to keep my posts, if any, on the short and light side.

Again, apologies to the board for some of my recent posts.

Enjoy the rest of the weekend!

Mr. Know-Nuttin'

Share
New Message
Please login to post a reply